MedCap (61MA) Stock Overview
A private equity firm specializing in investments in secondary direct, later stage, industry consolidation, add-on acquisitions, growth capital, middle market, mature, turnarounds, buyout. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 61MA from our risk checks.
61MA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
MedCap AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 52.20 |
| 52 Week High | SEK 59.60 |
| 52 Week Low | SEK 29.40 |
| Beta | 0.37 |
| 1 Month Change | -4.74% |
| 3 Month Change | 23.11% |
| 1 Year Change | 23.11% |
| 3 Year Change | 192.27% |
| 5 Year Change | n/a |
| Change since IPO | 169.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| 61MA | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 5.0% | 15.0% | 2.7% |
| 1Y | 23.1% | -13.4% | 14.5% |
Return vs Industry: 61MA exceeded the German Life Sciences industry which returned -15.2% over the past year.
Return vs Market: 61MA exceeded the German Market which returned 15% over the past year.
Price Volatility
| 61MA volatility | |
|---|---|
| 61MA Average Weekly Movement | 6.7% |
| Life Sciences Industry Average Movement | 6.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 12.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 61MA has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 61MA's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 583 | Anders Dahlberg | medcap.se/en/ |
MedCap AB (publ) is a private equity firm specializing in investments in secondary direct, later stage, industry consolidation, add-on acquisitions, growth capital, middle market, mature, turnarounds, buyout. It prefers to invest in healthcare equipment and services, biotechnology, life sciences, pharmaceuticals, med tech and assistive tech companies. The firm prefers to invest in small to medium size companies that are not listed on the stock exchange and are based in Nordic region and Northern Europe.
MedCap AB (publ) Fundamentals Summary
| 61MA fundamental statistics | |
|---|---|
| Market cap | €789.51m |
| Earnings (TTM) | €18.06m |
| Revenue (TTM) | €173.12m |
Is 61MA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 61MA income statement (TTM) | |
|---|---|
| Revenue | SEK 1.90b |
| Cost of Revenue | SEK 796.30m |
| Gross Profit | SEK 1.11b |
| Other Expenses | SEK 908.50m |
| Earnings | SEK 198.60m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Oct 24, 2025
| Earnings per share (EPS) | 13.20 |
| Gross Margin | 58.16% |
| Net Profit Margin | 10.43% |
| Debt/Equity Ratio | 4.4% |
How did 61MA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/03 20:58 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MedCap AB (publ) is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Bjorn Rydell | ABG Sundal Collier Sponsored |
| Hans Mähler | Nordea Markets |